Wealthy Families Play A Growing Role in European Biotech Financing
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
You may also be interested in...
German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.
Private German biotech CureVac wins validation for its RNA-vaccine technology platform with Sanofi Pasteur option deal and enters $33 million research collaboration co-funded by U.S defense department.
Shrinking Funding Rounds For European Biotechs Are No Surprise, But Series A Rounds Look Healthy, If Few
Nearly half (48%) of the 27 fundraisings by private European biotech companies so far this year have been for sums totaling $10 million or less, according to Elsevier's "Strategic Transactions" database. That's a significant increase over the same period in 2010, when less than 30% of financings were sub-$10 million.